Neutrocheck® recognised as breakthrough under UK Government's IDAP Scheme

52North has secured a place on the UK government's £10m Innovative Devices Access Pathway (IDAP) pilot programme, recognising the potential breakthrough status of its innovative solution, Neutrocheck®, a self-test for neutropenia.

This initiative, supported by a coalition including key regulatory and reimbursement authorities in the UK, including the Medicines and Healthcare products Regulatory Agency (MHRA), The National Institute for Health and Care Excellence (NICE), NHS England, Health Technology Wales, and Scottish Health Technology Group, aims to accelerate the development and NHS adoption of ground-breaking medical technologies.

Health minister Andrew Stephenson said:NHS staff need access to the latest technology to deliver the highest quality care for patients and cut waiting lists – one of our top five priorities... Our investment in these pioneering companies is part of our long-term plan for a faster, simpler and fairer health care system, and demonstrates our clear commitment to ensuring the UK is the most innovative economy in the world.”

The IDAP programme, currently in its pilot phase, is part of a broader strategy to ensure the NHS and its patients gain faster access to innovative technologies, aligning with the government's long-term healthcare system improvement plans. 

52North's selection highlights the company's role in advancing medical innovation and underscores IDAP's mission to bring transformative medical devices from concept to widespread NHS use, addressing critical patient needs and easing healthcare system pressures.

All news
S960 Digital logo for gov uk Copy